CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$53.85 USD
-0.99 (-1.81%)
Updated May 29, 2024 04:00 PM ET
After-Market: $52.98 -0.87 (-1.62%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
CRSP 53.85 -0.99(-1.81%)
Will CRSP be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRSP
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) Outperforms Industry on Rapid Pipeline Progress
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
Other News for CRSP
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
7 Stocks You Haven’t Heard of (That EVERYONE Should Own)
7 Biotech Stocks to Put on Your Breakthrough Radar
Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo
Nkarta: A Look Into Q1 Results And Upcoming Catalysts